Literature DB >> 27873006

Feasibility of omitting provocation test with 50 μg of acetylcholine in left coronary artery.

Yuichi Saito1, Hideki Kitahara2, Toshihiro Shoji2, Satoshi Tokimasa2, Takashi Nakayama2, Kazumasa Sugimoto2, Yoshihide Fujimoto2, Yoshio Kobayashi2.   

Abstract

According to the Japanese Circulation Society guideline of vasospastic angina, incremental doses of acetylcholine (ACh) are prescribed for coronary spasm provocation: 20 and 50 μg for the right coronary artery (RCA), and 20, 50 and 100 μg for the left coronary artery (LCA). However, provocation by low doses of ACh in patients with low vasoreactivity may be less needed, and the requirement of 50 μg of ACh for the LCA in these patients has not been evaluated. In the present study, patients who underwent ACh provocation test for both the RCA and LCA were included. The positive diagnosis of intracoronary ACh provocation test was defined as total or subtotal coronary artery narrowing (i.e., angiographic coronary artery spasm) accompanied by chest pain and/or ischemic electrocardiographic changes. Coronary artery constriction was visually evaluated and defined as coronary artery diameter reduction <25 or 25-90% in patients without angiographic coronary artery spasm by 20 µg of ACh in the LCA. There were 33 out of 249 patients (13%) with LCA spasm by 20 µg of ACh. In subjects without LCA spasm by 20 µg of ACh, patients with coronary constriction <25% (n = 101) by 20 µg of ACh in the LCA rarely showed coronary artery spasm induced by 50 μg of ACh in the LCA, in comparison to those with coronary constriction 25-90% (n = 115) (2.6 vs. 32.7%, p < 0.001). None of the patients with coronary constriction <25% by 20 µg of ACh in the LCA had cardiac complications associated with administration of ACh. In conclusion, omission of 50 µg of ACh in the LCA may be possible when there is little coronary artery constriction by 20 µg of ACh in the LCA during provocation test, leading to less contrast and shortens overall procedure time.

Entities:  

Keywords:  Acetylcholine provocation test; Diagnosis; Vasospastic angina

Mesh:

Substances:

Year:  2016        PMID: 27873006     DOI: 10.1007/s00380-016-0926-7

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  15 in total

1.  Safety and optimal protocol of provocation test for diagnosis of multivessel coronary spasm.

Authors:  Shozo Sueda; Toru Miyoshi; Yasuhiro Sasaki; Tomoki Sakaue; Hirokazu Habara; Hiroaki Kohno
Journal:  Heart Vessels       Date:  2014-11-01       Impact factor: 2.037

2.  Intracoronary Acetylcholine Provocation Testing - Omission of the 20-µg Dose Is Feasible in Patients Without Coronary Artery Spasm in the Other Coronary Artery.

Authors:  Yuichi Saito; Hideki Kitahara; Toshihiro Shoji; Satoshi Tokimasa; Takashi Nakayama; Kazumasa Sugimoto; Yoshihide Fujimoto; Yoshio Kobayashi
Journal:  Circ J       Date:  2016-06-28       Impact factor: 2.993

3.  Effect of pioglitazone on endothelial dysfunction after sirolimus-eluting stent implantation.

Authors:  Hideki Kitahara; Yoshio Kobayashi; Yo Iwata; Yoshihide Fujimoto; Issei Komuro
Journal:  Am J Cardiol       Date:  2011-05-10       Impact factor: 2.778

4.  Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013).

Authors: 
Journal:  Circ J       Date:  2014-09-30       Impact factor: 2.993

5.  Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm.

Authors:  K Okumura; H Yasue; K Matsuyama; K Goto; H Miyagi; H Ogawa; K Matsuyama
Journal:  J Am Coll Cardiol       Date:  1988-10       Impact factor: 24.094

6.  Need for documentation of guidelines for coronary artery spasm: an investigation by questionnaire in Japan.

Authors:  Shozo Sueda; Yousuke Izoe; Hiroaki Kohno; Hiroshi Fukuda; Tadao Uraoka
Journal:  Circ J       Date:  2005-11       Impact factor: 2.993

7.  3-year follow-up of patients with coronary artery spasm as cause of acute coronary syndrome: the CASPAR (coronary artery spasm in patients with acute coronary syndrome) study follow-up.

Authors:  Peter Ong; Anastasios Athanasiadis; Gabor Borgulya; Matthias Voehringer; Udo Sechtem
Journal:  J Am Coll Cardiol       Date:  2011-01-11       Impact factor: 24.094

8.  High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries).

Authors:  Peter Ong; Anastasios Athanasiadis; Gabor Borgulya; Heiko Mahrholdt; Juan Carlos Kaski; Udo Sechtem
Journal:  J Am Coll Cardiol       Date:  2012-02-14       Impact factor: 24.094

9.  Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm.

Authors:  H Yasue; Y Horio; N Nakamura; H Fujii; N Imoto; R Sonoda; K Kugiyama; K Obata; Y Morikami; T Kimura
Journal:  Circulation       Date:  1986-11       Impact factor: 29.690

10.  Importance of dual induction tests for coronary vasospasm and ventricular fibrillation in patients surviving out-of-hospital cardiac arrest.

Authors:  Yusuke Takagi; Satoshi Yasuda; Jun Takahashi; Morihiko Takeda; Masaharu Nakayama; Kenta Ito; Masanori Hirose; Yuji Wakayama; Koji Fukuda; Hiroaki Shimokawa
Journal:  Circ J       Date:  2009-03-03       Impact factor: 2.993

View more
  2 in total

1.  Feasibility and safety of outpatient cardiac catheterization with intracoronary acetylcholine provocation test.

Authors:  Yuichi Saito; Hideki Kitahara; Toshihiro Shoji; Satoshi Tokimasa; Takashi Nakayama; Kazumasa Sugimoto; Yoshihide Fujimoto; Yoshio Kobayashi
Journal:  Heart Vessels       Date:  2018-02-12       Impact factor: 2.037

2.  Dose-Response Relationship Between Intracoronary Acetylcholine and Minimal Lumen Diameter in Coronary Endothelial Function Testing of Women and Men With Angina and No Obstructive Coronary Artery Disease.

Authors:  Vedant S Pargaonkar; Justin H Lee; Eric K H Chow; Takeshi Nishi; Robyn L Ball; Yuhei Kobayashi; Takumi Kimura; David P Lee; Marcia L Stefanick; William F Fearon; Alan C Yeung; Jennifer A Tremmel
Journal:  Circ Cardiovasc Interv       Date:  2020-04-13       Impact factor: 7.514

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.